Sofosbuvir, Glecaprevir, Pibrentasvir, and Ribavirin as a Rescue Therapy in Difficult‐to‐Treat HCV Patients
- Others:
- Département d'Hépato-Gastroentérologie et de Transplantation Hépatique [CHU Saint-Eloi] ; Hôpital Saint Eloi (CHRU Montpellier) ; Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Université de Montpellier (UM)
- Université Côte d'Azur (UCA)
- Hôpital Archet 2 [Nice] (CHU)
- Institut Arnault Tzanck
- Service d'hépatologie et de gastroentérologie [Hôpital Saint-Joseph - Marseille] ; Aix Marseille Université (AMU)-Hôpital Saint-Joseph [Marseille]
Description
Pangenotypic direct-acting antiviral (DAA) drugs have an HCV cure rate of >95% in almost all treated patients.(1, 2) When DAA treatment fails, retreatment must be guided by virus resistance profiles, and phase 3 trials have reported sustained virological responses (SVR) of 96%-98% after a 12-week course of sofosbuvir (SOF), velpatasvir (VEL), and voxilaprevir (VOX).(3) However, the management is more uncertain after SOF/VEL/VOX failure, and there is still insufficient evidence to support a particular retreatment. For instance, Dietz et al.(4) reported 77% SVR at 12 weeks (SVR12) in patients with different HCV profiles retreated with glecaprevir (GLE)/pibrentasvir (PIB), SOF, and ribavirin (RBV) for 12-24 weeks after SOF/VEL/VOX failure.
Abstract
International audience
Additional details
- URL
- https://hal.umontpellier.fr/hal-03665135
- URN
- urn:oai:HAL:hal-03665135v1
- Origin repository
- UNICA